These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30234515)

  • 21. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations.
    Milder DA; Milder TY; Kam PCA
    Anaesthesia; 2018 Aug; 73(8):1008-1018. PubMed ID: 29529345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin.
    Bonanni FB; Fei P; Fitzpatrick LL
    Surg Obes Relat Dis; 2016 Jan; 12(1):e11-2. PubMed ID: 26686305
    [No Abstract]   [Full Text] [Related]  

  • 27. Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes.
    Raven LM; Muir CA; Greenfield JR
    Med J Aust; 2023 Oct; 219(7):293-294. PubMed ID: 37549922
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery.
    Lau A; Bruce S; Wang E; Ree R; Rondi K; Chau A
    Can J Anaesth; 2018 Feb; 65(2):188-193. PubMed ID: 29168157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
    Ramirez Tello EM; Orellana-Barrios MA; Nugent K
    Am J Med Sci; 2016 Jun; 351(6):634-5. PubMed ID: 27238930
    [No Abstract]   [Full Text] [Related]  

  • 31. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Unusual Case of Metabolic Acidosis: Clinical Case Education.
    Abu-Amer N; Dinour D; Mini S; Beckerman P
    Isr Med Assoc J; 2019 Nov; 21(11):766-768. PubMed ID: 31713370
    [No Abstract]   [Full Text] [Related]  

  • 33. [Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].
    Breuer TGK; Kampmann K; Wutzler A; Steinfort C; Uhl W; Schmidt WE; Meier JJ
    Internist (Berl); 2018 Mar; 59(3):282-287. PubMed ID: 28864828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
    Fralick M; Kim SC; Schneeweiss S; Kim D; Redelmeier DA; Patorno E
    Ann Intern Med; 2019 Feb; 170(3):155-163. PubMed ID: 30597484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report.
    Lane S; Paskar D; Hamed S; Goffi A
    A A Pract; 2018 Jul; 11(2):46-48. PubMed ID: 29634546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
    Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
    J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
    Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication].
    Rotsel E; Pietsch U
    Anaesthesist; 2020 Jan; 69(1):49-51. PubMed ID: 31807797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Euglycemic ketoacidosis : a complication of SGLT2 inhibitors].
    Mizuno A; Lolachi S; Pernet A
    Rev Med Suisse; 2017 May; 13(565):1164-1167. PubMed ID: 28639760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.